Is JAK inhibition an option in the treatment of interstitial lung disease in rheumatoid arthritis?
© 2023. The Author(s)..
A 69-year-old male patient with seropositive erosive rheumatoid arthritis (RA) presented to our clinic due to progressive dyspnea. High-resolution computed tomography (HRCT) and immunological bronchioalveolar lavage revealed ground-glass opacities and a lymphocytic alveolitis caused by interstitial lung disease (ILD) in RA. Considering previous forms of treatment, disease-modifying antirheumatic drug (DMARD) treatment was switched to tofacitinib. Tofacitinib treatment demonstrated a 33% reduction in ground-glass opacities by artificial intelligence-based quantification of pulmonary HRCT over the course of 6 months, which was associated with an improvement in dyspnea symptoms. In conclusion, tofacitinib represents an effective anti-inflammatory therapeutic option in the treatment of RA-ILD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Zeitschrift fur Rheumatologie - (2023) vom: 17. Okt. |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Ist JAK-Hemmung eine Option in der Behandlung der interstitiellen Lungenerkrankung bei einer rheumatoiden Arthritis? |
|---|
| Beteiligte Personen: |
Hoffmann, Tobias [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 17.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s00393-023-01434-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363398570 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363398570 | ||
| 003 | DE-627 | ||
| 005 | 20231226093249.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00393-023-01434-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363398570 | ||
| 035 | |a (NLM)37847297 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Hoffmann, Tobias |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is JAK inhibition an option in the treatment of interstitial lung disease in rheumatoid arthritis? |
| 246 | 3 | 3 | |a Ist JAK-Hemmung eine Option in der Behandlung der interstitiellen Lungenerkrankung bei einer rheumatoiden Arthritis? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a A 69-year-old male patient with seropositive erosive rheumatoid arthritis (RA) presented to our clinic due to progressive dyspnea. High-resolution computed tomography (HRCT) and immunological bronchioalveolar lavage revealed ground-glass opacities and a lymphocytic alveolitis caused by interstitial lung disease (ILD) in RA. Considering previous forms of treatment, disease-modifying antirheumatic drug (DMARD) treatment was switched to tofacitinib. Tofacitinib treatment demonstrated a 33% reduction in ground-glass opacities by artificial intelligence-based quantification of pulmonary HRCT over the course of 6 months, which was associated with an improvement in dyspnea symptoms. In conclusion, tofacitinib represents an effective anti-inflammatory therapeutic option in the treatment of RA-ILD | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Artificial intelligence-based quantification of pulmonary high-resolution computed tomography | |
| 650 | 4 | |a Interstitial lung disease | |
| 650 | 4 | |a JAK inhibition | |
| 650 | 4 | |a Quantitative lung imaging | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 700 | 1 | |a Teichgräber, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Lassen-Schmidt, Bianca |e verfasserin |4 aut | |
| 700 | 1 | |a Kroegel, Claus |e verfasserin |4 aut | |
| 700 | 1 | |a Krämer, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Förster, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Renz, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Oelzner, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Böttcher, Joachim |e verfasserin |4 aut | |
| 700 | 1 | |a Franz, Marcus |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Gunter |e verfasserin |4 aut | |
| 700 | 1 | |a Güttler, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeil, Alexander |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zeitschrift fur Rheumatologie |d 1974 |g (2023) vom: 17. Okt. |w (DE-627)NLM000024287 |x 1435-1250 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:17 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00393-023-01434-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 17 |c 10 | ||